HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

DOCS

Doximity, Inc. (Russell 2000)

Healthcare — Health Information Services

Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Buy 2.4 / 5 18 analysts
$21.44
+$0.45 (+2.14%)
Target: $24.61 (14.8%)
Sign in to add DOCS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$3.85B
P/E Ratio (TTM)21.88
Forward P/E13.45
EPS (TTM)$0.98
Dividend Yield-
Profit Margin30.40%
Revenue Growth5.10%
ROE19.28%
Debt/Equity1.07
Recommendation Buy 2.4
Analyst Target$24.61
Analysts18
Indexes Russell 2000

Technical Indicators

RSI (14)47.6
Beta1.29
SMA 20$21.60
SMA 40$21.11
52-Week High$76.51
52-Week Low$17.15
50-Day Avg$20.81
200-Day Avg$34.47
Avg Volume$4.04M
Volume$3.65M

Performance Analysis

BULLISH

DOCS shows predominantly bullish signals based on its fundamentals and technicals.

+ Trading near its 52-week low ($17.15), which could present a value opportunity.
~ RSI at 47.6 is in neutral territory.
~ Modest revenue growth of 5.1% year-over-year.
+ Healthy profit margin of 30.4%.
+ Wall Street consensus is "Buy" from 18 analysts.
+ Average analyst target of $24.61 implies 14.8% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report